Editor’s Note: The Mid-Atlantic region is chocked full of high-profile health care companies that call Maryland home. Many of them are led by brilliant, innovative leaders who just happen to also be women.
Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc.
Rachel K. King co-founded GlycoMimetics, Inc. (GMI) in 2003 and has served as its CEO since its inception. In 2013 and 2014 King shepherded the oncology-focused biotech company through the IPO process. Under her leadership, GMI secured an exclusive global licensing agreement with Pfizer for work on a drug to help sickle-cell blood problems. She was also successful in raising significant capital for the company. In 2013 King was honored with the Executive of the Year Award from the Maryland Tech Council in recognition of her leadership and innovation in the technology and life science community in Maryland.
Prior to GMI, King was Executive in Residence at New Enterprise Associates, a leading venture capital firm. This followed her time as a Senior Vice President at Novartis Corporation, which followed 10 years with Genetic Therapy, Inc. where she moved with the company through its early stages, IPO and eventual sale to Novartis Corporation. After the sale she served as CEO for the wholly owned subsidiary.
King also worked previously for ALZA Corporation in Palo Alto, and at Bain and Company in Boston. She is on the board of the Biotechnology Innovation Organization and other biotech boards. She holds an M.B.A. from Harvard Business School.
Click here to read more via I95Business